AIMI - Medical Information for Datroway® (datopotamab deruxtecan-dlnk) | AstraZeneca Oncology

Medical Information on Datroway® (datopotamab deruxtecan-dlnk) Available via AIMI

AstraZeneca's Medical Virtual Assistant, AIMI, provides healthcare professionals with timely, accurate, and non-promotional medical information. If you have questions about DATROWAY, AIMI is available to support your clinical decision-making needs.

How to Access Medical Information on DATROWAY

Start a conversation with AIMI to receive tailored medical information about DATROWAY. AIMI is available 24/7 and supports scientific, evidence-based inquiries from healthcare professionals.

Chat with AIMI

How AIMI Can Help

What are the approved indications for DATROWAY
Are there biomarker requirements for DATROWAY therapy?
Is DATROWAY approved for elderly patients?
Is DATROWAY approved for children?
What is DATROWAY's storage stability?
What is pharmacokinetics profile of DATROWAY?
What is the mechanism of action of DATROWAY?
How can I enroll my patient in any DATROWAY's trial?
I would like to discuss DATROWAY with an MSL

AIMI can provide detailed, evidence-based answers to these and other questions to healthcare professionals.

This information is intended to be a concise summation of representative clinical trial data, rather than being all-inclusive; therefore, all available published literature may not be incorporated into this response.